Catalyst Biosciences Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios deCatalyst Biosciences aumenten en 75.6% al año. Se prevé que el BPA de grow sea de 75.5% al año.

Información clave

75.6%

Tasa de crecimiento de los beneficios

75.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	32.3%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	15 Aug 2023

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:HGF2 - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	N/A	-1	0	N/A	1
12/31/2024	N/A	-1	0	N/A	1
12/31/2023	N/A	-6	N/A	N/A	1
9/30/2023	N/A	-44	-13	-13	N/A
6/30/2023	N/A	-48	-17	-17	N/A
3/31/2023	N/A	7	-27	-27	N/A
12/31/2022	1	-8	-33	-33	N/A
9/30/2022	3	12	-49	-49	N/A
6/30/2022	6	-8	-64	-64	N/A
3/31/2022	7	-80	-72	-71	N/A
12/31/2021	7	-88	-85	-84	N/A
9/30/2021	7	-87	-89	-88	N/A
6/30/2021	6	-77	-80	-80	N/A
3/31/2021	6	-75	-75	-75	N/A
12/31/2020	21	-56	-55	-55	N/A
9/30/2020	19	-51	-41	-41	N/A
6/30/2020	18	-48	-37	-37	N/A
3/31/2020	16	-44	-34	-33	N/A
12/31/2019	N/A	-55	-44	-44	N/A
9/30/2019	N/A	-52	-45	-45	N/A
6/30/2019	N/A	-47	-43	-42	N/A
3/31/2019	N/A	-40	-39	-38	N/A
12/31/2018	0	-30	-29	-29	N/A
9/30/2018	0	-25	-26	-26	N/A
6/30/2018	1	-23	-24	-24	N/A
3/31/2018	1	-26	-21	-21	N/A
12/31/2017	1	-26	-20	-20	N/A
9/30/2017	1	-24	-19	-19	N/A
6/30/2017	1	-22	N/A	-19	N/A
3/31/2017	1	-17	N/A	-18	N/A
12/31/2016	0	-17	N/A	-18	N/A
9/30/2016	0	-18	N/A	-19	N/A
6/30/2016	0	-19	N/A	-23	N/A
3/31/2016	1	-15	N/A	-21	N/A
12/31/2015	2	-15	N/A	-19	N/A
9/30/2015	2	-11	N/A	-16	N/A
6/30/2015	3	-7	N/A	-7	N/A
3/31/2015	2	-8	N/A	-8	N/A
12/31/2014	2	-7	N/A	-6	N/A
12/31/2013	1	-10	N/A	-6	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. tasa de ahorro: HGF2 se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios frente mercado: HGF2 se prevé que siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: HGF2 se prevé que siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de HGF2 crezcan más rápido que el mercado de German.

Ingresos de alto crecimiento: HGF2 no tendrá ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Futura rentabilidad financiera (ROE): Datos insuficientes para determinar si la Rentabilidad de los fondos propios de HGF2 se prevé elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Catalyst Biosciences Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2022

Recent updates

Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. (NasdaqCM:CBIO) in a reverse merger transaction.

Catalyst Biosciences, Inc. announced that it has received $4.999815 million in funding from GNI USA, Inc.

Catalyst Biosciences Announces Update on Letter from Nasdaq Regarding Minimum Bid Price Requirement

Full year 2022 earnings released: US$0.26 loss per share (vs US$2.87 loss in FY 2021)

Catalyst Biosciences, Inc. Terminates Grant Blouse from the Position as the Chief Scientific Officer

Inaugural dividend of US$0.24 per share

Insufficient new directors

Catalyst Biosciences, Inc. (NasdaqCM:CBIO) agreed to acquire unknown majority stake in Beijing Continent Pharmaceutical Co., Ltd. from GNI Group Ltd. (TSE:2160) and Shanghai Genomics, Inc.

Catalyst Biosciences, Inc. (NasdaqCM:CBIO) agreed to acquire unknown majority stake in Beijing Continent Pharmaceutical Co., Ltd. from GNI Group Ltd. (TSE:2160) and Shanghai Genomics, Inc.

Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.80 loss in 3Q 2021)

Catalyst Biosciences Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Insider recently sold €289k worth of stock

Insider recently sold €513k worth of stock

Inaugural dividend of US$1.43 per share

Catalyst Biosciences, Inc. Declares Special One-Time Cash Dividend, Payable on September 20, 2022

Catalyst Biosciences, Inc. Announces Dismissal of Jds1 Litigation

Second quarter 2022 earnings released: EPS: US$1.64 (vs US$0.64 loss in 2Q 2021)

Forecast to breakeven in 2022

JEC II Associates, LLC Reaches an Agreement Catalyst Biosciences

JDS1 LLC Issues an Investor Presentation to Shareholders of Catalyst Biosciences Inc

JDS1, LLC Provides Information to the Shareholders

JEC II Associates Engages in Discussions with Catalyst Biosciences

Insider recently bought €891k worth of stock

JDS1, LLC Provides Information to the Shareholders

Catalyst Biosciences, Inc., Annual General Meeting, Aug 15, 2022

Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million.

Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million.

First quarter 2022 earnings released: US$0.46 loss per share (vs US$0.79 loss in 1Q 2021)

JDS1 Files a Complaint against Catalyst Biosciences

JDS1 Provides Information to Shareholders of Catalyst Biosciences

Full year 2021 earnings released: US$2.87 loss per share (vs US$2.93 loss in FY 2020)

Julian D. Singer Provides Information to Shareholders of Catalyst Biosciences

Julian D. Singer Provides Information to Shareholders of Catalyst Biosciences

Julian D. Singer Provides Information to Shareholders of Catalyst Biosciences

Julian Singer Sends Letter to Catalyst Biosciences

Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency

Third quarter 2021 earnings released: US$0.80 loss per share (vs US$0.73 loss in 3Q 2020)

FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency

Second quarter 2021 earnings released: US$0.64 loss per share (vs US$0.96 loss in 2Q 2020)

Catalyst Biosciences Announces First Patient Screened for CFI Deficiency in Its CB 4332 Screening and Natural History of Disease Studies

Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from Russell 3000E Value Index

Catalyst Biosciences, Inc. Announces Initiation of Dosing in the Company's Phase 1/2 Study (MAA-202) of Marzeptacog Alfa

Catalyst Biosciences Announces the Dosing of the First Patient in the Crimson 1 Study, the Company's Phase 3 Registration Trial (Maa-304 - Crimson 1)

Revenue beats expectations

New 90-day high: €6.00

Catalyst Biosciences Presents Pre-clinical SQ Treatment of Bleeds Data from its Marzeptacog alfa (activated) (MarzAA) Program at the 14th Annual EAHAD Congress

New 90-day high: €5.50

Catalyst Biosciences, Inc. Receives FDA Fast Track Designation for Subcutaneous Marzaa for the Treatment of Episodic Bleeding in Hemophilia A or B with Inhibitors

New 90-day high: €5.40

New 90-day low: €3.70

New 90-day low - €4.18

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento